Prostate Cancer

A Vanderbilt study found that prostate cancer polygenic risk score has limited utility for enhancing prostate cancer screening. Read More

Vanderbilt researchers suggest that to reduce treatment-related regret for men with localized prostate cancer, treatment preparation should focus on shared decision-making and aligning patient expectations with treatment toxicity. Read More

An indirect comparative effectiveness study using published data suggests that the targeted therapy olaparib should be re-evaluated for treating metastatic prostate cancer. Read More

Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets. Read More

Surgery for prostate cancer—the most prevalent cancer in men—soon could no longer require cutting through healthy tissue and nerves. Surgeons instead may work with minuscule robots developed at the Vanderbilt Institute for Surgery and Engineering. Read More

An international group of researchers including Vanderbilt epidemiologists has identified new DNA methylation biomarkers associated with prostate cancer risk. Read More

Vanderbilt researchers have identified haplotypes, ancestral fragments of DNA, that are associated with hereditary prostate cancer in a first-of-its-kind genomic study made possible by the study of prostate cancer patients with family histories of the disease. Read More

An analysis of more than 140,000 people of European ancestry has identified blood protein biomarkers associated with prostate cancer risk. Read More

Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer. Read More

Survivors of prostate cancer are being sought to provide feedback for a Vanderbilt University project trying to improve care. Read More

In 2012, the United States Preventive Services Task Force recommended that men of all ages should not be routinely screened for levels of prostate-specific antigen (PSA). These are the blood tests to detect the possibility of prostate cancer. That group now recommends that men ages 55 to 69 should talk with their doctors and make well-informed individual decisions about the potential harms and benefits of PSA screening, and treatment if cancer is found. Read More

“When it’s you, it’s a whole different feeling,” Orrin Ingram said, gazing at logs burning in the fireplace. Read More

In 2012, the United States Preventive Services Task Force recommended that men of all ages should not be routinely screened for levels of prostate-specific antigen (PSA). That group now recommends that men ages 55 to 69 should talk with their doctors and make well-informed individual decisions about the potential harms and benefits of PSA screening, and treatment if cancer is found. Read More

In 2012, the United States Preventive Services Task Force recommended that men of all ages should not be routinely screened for levels of prostate-specific antigen (PSA). These are the blood tests to detect the possibility of prostate cancer. Read More

A federal task force has changed its recommendation about prostate cancer screening for some older men. The United States Preventive Services Task Force (USPSTF) now recommends that men between the ages of 55 to 69 consult with their physicians about getting routine screening blood tests to detect prostate cancer. Read More

Faced with the negative quality-of-life effects from surgery and radiation treatments for prostate cancer, low risk patients may instead want to consider active surveillance with their physician, according to a study released Tuesday by the Journal of the American Medical Association (JAMA). Read More

Vanderbilt University Medical Center is the world’s first site to treat a patient in the TULSA-PRO Ablation Clinical Trial (TACT), which employs an emerging therapy that uses MRI guidance and robotically driven therapeutic ultrasound to obtain precise prostate cancer tissue ablation. Read More

The 3 million prostate cancer survivors in the United States are likely to die from something other than cancer, thanks to early detection, effective treatment and the disease’s slow progression. Read More

"Messages of Hope: Advances in Prostate Cancer Prevention, Research and Treatment," a free program for prostate cancer survivors, caregivers and health professionals, will be held Friday, Dec. 11, from 9 to 11 a.m. at the Vanderbilt-Ingram Cancer Center. Read More

Beginning this week, Vanderbilt men will have a good excuse to ignore their razors and let their facial hair grow. November has been dubbed “Movember,” a time when men are encouraged to grow a moustache to raise funds and awareness for prostate cancer. Read More